Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma.
作者信息
Merhi Maysaloun, Raza Afsheen, Inchakalody Varghese, Zar Abdul Rahman, Uddin Shahab, Dermime Said
机构信息
National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Translational Cancer Research Facility, Hamad Medical Corporation, Doha, Qatar.
出版信息
Ann Transl Med. 2019 Mar;7(Suppl 1):S22. doi: 10.21037/atm.2019.01.72.
Abstract
摘要
相似文献
1
Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma.晚期头颈部鳞状细胞癌患者的免疫治疗策略
Ann Transl Med. 2019 Mar;7(Suppl 1):S22. doi: 10.21037/atm.2019.01.72.
2
Immunotherapy in the management of squamous cell carcinoma of the head and neck.免疫疗法在头颈部鳞状细胞癌治疗中的应用
Br J Oral Maxillofac Surg. 2019 Dec;57(10):957-966. doi: 10.1016/j.bjoms.2019.08.002. Epub 2019 Oct 22.
3
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.帕尼单抗联合放疗对比放化疗用于治疗不可切除的局部晚期头颈部鳞状细胞癌患者（CONCERT-2）：一项随机、对照、开放标签的 2 期临床试验。
Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15.
4
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.2-甲氧基雌二醇抑制缺氧诱导因子1α、肿瘤生长和血管生成，并增强紫杉醇在头颈部鳞状细胞癌中的疗效。
Clin Cancer Res. 2004 Dec 15;10(24):8665-73. doi: 10.1158/1078-0432.CCR-04-1393.
5
6
Immunotherapy for head and neck cancer patients: shifting the balance.头颈部癌症患者的免疫治疗：改变平衡。
Immunotherapy. 2013 Jan;5(1):49-61. doi: 10.2217/imt.12.135.
7
Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.采用卡铂进行的头颈部鳞状细胞癌根治性放化疗。
Laryngoscope. 2017 Oct;127(10):2260-2264. doi: 10.1002/lary.26554. Epub 2017 Mar 8.
8
Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.西妥昔单抗联合放疗或化疗治疗晚期头颈部鳞状细胞癌的评估。
Shanghai Kou Qiang Yi Xue. 2008 Feb;17(1):1-5.
9
Blockade of adenosine A2A receptor enhances CD8 T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.腺苷A2A受体阻断增强头颈部鳞状细胞癌中CD8 T细胞反应并减少调节性T细胞
Mol Cancer. 2017 Jun 7;16(1):99. doi: 10.1186/s12943-017-0665-0.
10
Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.头颈部癌的免疫疗法——科学原理、当前治疗选择及未来方向。
Swiss Med Wkly. 2018 May 14;148:w14625. doi: 10.4414/smw.2018.14625. eCollection 2018.
引用本文的文献
1
Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review).用于预测头颈部癌症对免疫检查点阻断反应的生物标志物和 3D 模型（综述）。
Int J Oncol. 2022 Jul;61(1). doi: 10.3892/ijo.2022.5378. Epub 2022 Jun 1.
2
Molecular Pathology of Lung Cancer.肺癌的分子病理学
Cold Spring Harb Perspect Med. 2022 Mar 1;12(3):a037812. doi: 10.1101/cshperspect.a037812.
本文引用的文献
1
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.循环中可溶性 PD-L1 表达作为胃癌复发和预后的预测标志物：组织和血清 PD-L1 表达的临床负担直接比较。
Ann Surg Oncol. 2019 Mar;26(3):876-883. doi: 10.1245/s10434-018-07112-x. Epub 2018 Dec 18.
2
Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.头颈部鳞状细胞癌对程序性细胞死亡蛋白-1 靶向治疗的反应及免疫标志物的差异表达：一例报告。
Front Immunol. 2018 Jul 30;9:1769. doi: 10.3389/fimmu.2018.01769. eCollection 2018.
3
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.外泌体 PD-L1 有助于免疫抑制，并与抗 PD-1 反应相关。
Nature. 2018 Aug;560(7718):382-386. doi: 10.1038/s41586-018-0392-8. Epub 2018 Aug 8.
4
Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target.爱泼斯坦-巴尔病毒在头颈癌发病机制中的作用及其作为免疫治疗靶点的潜力。
Front Oncol. 2018 Jul 6;8:257. doi: 10.3389/fonc.2018.00257. eCollection 2018.
5
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.免疫识别导致转移性乳腺癌完全持久消退的体细胞突变。
Nat Med. 2018 Jun;24(6):724-730. doi: 10.1038/s41591-018-0040-8. Epub 2018 Jun 4.
6
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.循环可溶性程序性死亡配体-1在实体瘤患者中的预后意义：一项荟萃分析。
Medicine (Baltimore). 2018 Jan;97(3):e9617. doi: 10.1097/MD.0000000000009617.
7
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.帕博利珠单抗用于亚太地区晚期头颈部鳞状细胞癌患者：KEYNOTE-012研究分析
Cancer Sci. 2018 Mar;109(3):771-776. doi: 10.1111/cas.13480. Epub 2018 Feb 8.
8
An immunogenic personal neoantigen vaccine for patients with melanoma.一种用于黑色素瘤患者的免疫原性个人新抗原疫苗。
Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5.
9
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.可溶性 PD-L1 作为接受检查点阻断治疗的恶性黑色素瘤的生物标志物。
Cancer Immunol Res. 2017 Jun;5(6):480-492. doi: 10.1158/2326-6066.CIR-16-0329. Epub 2017 May 18.
10
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.病毒诱导的上皮癌成功免疫治疗中免疫原性肿瘤抗原的格局
Science. 2017 Apr 14;356(6334):200-205. doi: 10.1126/science.aak9510.
Zotero 插件